Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness of peginterferon alfa-2a vs alfa-2b plus ribavirin in chronic hepatitis C genotypes 2 and 3 in Thailand
TCTR20200313004Completed
- Start
- Jul 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of interferon alfa, peginterferon alfa-2b and ribavirin in chronic hepatitis C (CHC) and hepatitis C virus infection (2 arms), sponsored by None. Primary endpoint: Sustained virologic response (SVR). Started Jul 2017; status: completed.
02
Drugs
interferon alfapeginterferon alfa-2bribavirin
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on TCTR20200313004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200313004.